Core Insights - Hutchison China MediTech Limited (HCM) will present updated data on its proprietary compounds at two major conferences in September 2025, specifically the World Lung Cancer Conference (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan, China [1] Group 1: Upcoming Presentations - HCM will showcase the latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for the treatment of non-small cell lung cancer at the WCLC [1] - The first human Phase I clinical trial data for HMPL-653, a novel selective and potent CSF-1R inhibitor, will be presented at the CSCO annual meeting [1] Group 2: Drug Development - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1]
和黄医药(00013)将于2025年世界肺癌大会和中国临床肿瘤学会2025年年会公布自主研发的化合物的数项研究的最新数据